Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

April 10, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

June 21, 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

News Conference News SCAI 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

May 25, 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

As Paclitaxelgate Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

November 27, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

January 29, 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

January 28, 2020

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

November 22, 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

November 06, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.